<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00294047</url>
  </required_header>
  <id_info>
    <org_study_id>104820</org_study_id>
    <nct_id>NCT00294047</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older</brief_title>
  <official_title>A Study to Evaluate Safety, Immunogenicity and Efficacy of GSK Biologicals HPV-16/18 L1/AS04 Vaccine Administered Intramuscularly According to a Three-dose Schedule (0, 1, 6 Month) in Healthy Adult Female Subjects Aged 26 Years and Above</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This is a multicentre study in which women were planned to receive either the Human
      Papillomavirus Vaccine (HPV) vaccine or control. Under Protocol Amendment 3, study
      participation will last approximately 48 months and involves a total of eleven scheduled
      visits. Under Protocol Amendment 4, study participation will last up to 84 months and
      involves a maximum of seventeen scheduled visits.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Protocol Posting has been updated due to protocol amendment 5 and in order to comply with
      the FDA Amendment Act, Sep 2007.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18 and/or With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection.</measure>
    <time_frame>Up to Month 48</time_frame>
    <description>CIN1+ = CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.
Persistent HPV infection = detection of the same HPV type(s) by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.
DNA- and sero-/+: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and 6 and seronegative/positive (sero-/+) at Month 0 for the corresponding HPV-type by Enzyme-linked Immunosorbent Assay (ELISA)
Overall: subjects DNA- at Month 0 and 6 for the corresponding HPV-type, regardless of initial serostatus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 or HPV-18 and/or With Histopathologically-CIN1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Using the HPV Type Assignment Algorithm (TAA).</measure>
    <time_frame>Up to Month 48</time_frame>
    <description>CIN1+ = CIN grades 1, 2 and 3, AIS and invasive cervical cancer. Persistent cervical HPV infection (6-month definition) = detection of the same HPV type(s) by PCR in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.
DNA- and sero-/+: subjects HPV DNA negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by ELISA at baseline (Month 0).
Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18 and/or With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection.</measure>
    <time_frame>Up to Month 84</time_frame>
    <description>CIN1+ = CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer. Persistent HPV infection = detection of the same HPV type(s) by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval. - DNA- and sero-/+: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and 6 and seronegative/positive (sero-/+) at Month 0 for the corresponding HPV-type by Enzyme-linked Immunosorbent Assay (ELISA) - Overall: subjects DNA- at Month 0 and 6 for the corresponding HPV-type, regardless of initial serostatus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 or HPV-18 and/or With Histopathologically-CIN1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Using the HPV Type Assignment Algorithm (TAA).</measure>
    <time_frame>Up to Month 84</time_frame>
    <description>CIN1+ = CIN grades 1, 2 and 3, AIS and invasive cervical cancer. Persistent cervical HPV infection (6-month definition) = detection of the same HPV type(s) by PCR in cervical samples at 2 consecutive evaluations over approximately a 6-month interval. - DNA- and sero-/+: subjects HPV DNA negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by ELISA at baseline (Month 0). - Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18</measure>
    <time_frame>Up to Month 48</time_frame>
    <description>Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type(s) by PCR in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.
Detection was done in:
DNA- and sero-/+: subjects HPV DNA negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by ELISA at baseline (Month 0).
Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Persistent Infection (12-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18</measure>
    <time_frame>Up to Month 48</time_frame>
    <description>Persistent cervical HPV infection (12-month definition) was defined as the detection of the same HPV type(s) PCR in cervical samples at all available time points over approximately a 12-month interval (evaluations are planned at approximately 6-month intervals).
DNA- and sero-/+: subjects HPV DNA negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by ELISA at baseline (Month 0).
Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Persistent Infection (6-month Definition) With Oncogenic HPV Types Individually or in Combinations.</measure>
    <time_frame>Up to Month 48</time_frame>
    <description>Persistent cervical HPV infection (6-month definition) = detection of the same HPV type(s) by PCR in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.
Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
Detection was done in subjects HPV DNA- for the corresponding HPV type at baseline (at month 0 and Month 6) regardless of initial serostatus.
HPV-HRW=All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18. HPV-HR=High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Persistent Infection (12-month Definition) With Oncogenic HPV Types Individually or in Combinations.</measure>
    <time_frame>Up to Month 48</time_frame>
    <description>Persistent HPV infection (12-month definition) = detection of the same HPV type(s) by PCR in cervical samples at available time points over approximately a 12-month interval (evaluations are planned at approximately 6-month intervals).
Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
subjects HPV DNA- for the corresponding HPV type at Month 0 6, regardless of initial serostatus.
HPV-HRW=All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18 HPV-HR=High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 , 68</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With HPV-16 and/or -18 Cervical Infection Detected Within the Lesional Component of the Cervical Tissue Specimen</measure>
    <time_frame>Up to Month 48</time_frame>
    <description>CIN2+ was defined as CIN grades 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.
Detection was done in:
DNA- and sero-: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative (sero-) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0).
Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.
Note: Results for seropositive status were not analysed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Within the Lesional Component of the Cervical Tissue Specimen</measure>
    <time_frame>Up to Month 48</time_frame>
    <description>CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.
Detection was done in:
DNA- and sero-/+: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0).
Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Within the Lesional Component of the Cervical Tissue Specimen</measure>
    <time_frame>Up to Month 48</time_frame>
    <description>CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.
Detection was done on all subjects irrespective of their baseline HPV DNA and serostatus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Irrespective of HPV Cervical Infection and Irrespective of Baseline HPV DNA Status</measure>
    <time_frame>Up to Month 48</time_frame>
    <description>CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.
Detection was done on all subjects irrespective of their baseline HPV DNA status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Cytological Abnormalities Associated With HPV-16 or HPV-18 Cervical Infection</measure>
    <time_frame>Up to Month 48</time_frame>
    <description>Cytological abnormalities = atypical squamous cells of undetermined significance (ASC-US).
Detection was done in:
DNA- and sero-: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative (sero-) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0).
Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.
Results for seropositive status were not analysed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Cytological Abnormalities Associated With Oncogenic HPV Types Individually or in Combinations</measure>
    <time_frame>Up to Month 48</time_frame>
    <description>Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
Detection was done in subjects who were HPV DNA negative for the corresponding HPV type at baseline (at month 0 and Month 6) regardless of initial serostatus.
HRW-HPV= All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18 HPV-HR= High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Histopathologically Confirmed Reduction of Local Cervical Therapy</measure>
    <time_frame>Up to Month 48</time_frame>
    <description>Detection was done on all subjects irrespective of their baseline HPV DNA status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With First Colposcopy</measure>
    <time_frame>Up to Month 48</time_frame>
    <description>Detection was done on all subjects irrespective of their baseline HPV DNA status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18 and/or With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection</measure>
    <time_frame>Up to Month 48</time_frame>
    <description>Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type(s) by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.
CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.
Detection was done on all subjects irrespective of their baseline HPV DNA and serostatus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 or HPV-18 and/or With Histopathologically-confirmed CIN1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Using the HPV Type Assignment Algorithm (TAA).</measure>
    <time_frame>Up to Month 48</time_frame>
    <description>Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type(s) by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.
Detection was done on all subjects irrespective of their baseline HPV DNA and serostatus.
The lesion was assigned to an HPV type found in the lesion if (1) the same HPV type was found in at least 1 of the 2 (closest) preceding cytology samples, or (2) none of the HPV types found in the lesion were found in any of the 2 preceding cytology samples (isolate HPV types)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted Subjects Against HPV-16 in the Immunogenicity Subset.</measure>
    <time_frame>At pre-vaccination and at Month 7, 12, 18, 24, 36, 48, 60, 72 and 84</time_frame>
    <description>Seroconversion was defined as the appearance of antibodies (i.e.; titre greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.
HPV-16 assay cut-off value was defined as greater than or equal to 8 ELISA units per millilitre (EL.U/mL). Seronegative (Sero-) subjects are subjects who had an antibody concentration below 8 EL.U/mL prior to vaccination. Seropositive (Sero+) subjects are subjects who had an antibody concentration equal to or above 8 EL.U/mL prior to vaccination.
Immuno subset=subjects from selected sites N≥1000, at least 250 per region</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted Subjects Against HPV-18 in the Immunogenicity Subset.</measure>
    <time_frame>At pre-vaccination and at Month 7, 12, 18, 24, 36, 48, 60, 72 and 84</time_frame>
    <description>Seroconversion was defined as the appearance of antibodies (i.e.; titre greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.
HPV-18 assay cut-off value was defined as greater than or equal to 7 ELISA units per millilitre (EL.U/mL). Seronegative (Sero-) subjects are subjects who had an antibody concentration below 7 EL.U/mL prior to vaccination. Seropositive (Sero+) subjects are subjects who had an antibody concentration equal to or above 7 EL.U/mL prior to vaccination.
Immuno subset=subjects from selected sites N≥1000, at least 250 per region</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations (GMCs) Against HPV-16 Antibody in the Immunogenicity Subset.</measure>
    <time_frame>At pre-vaccination and at Month 7, 12, 18, 24, 36, 48, 60, 72 and 84</time_frame>
    <description>GMCs were expressed in ELISA units per milliliter (EL.U/mL).
Seronegative (Sero-) subjects are subjects who had an antibody concentration below 8 EL.U/mL prior to vaccination. Seropositive (Sero+) subjects are subjects who had an antibody concentration equal to or above 8 EL.U/mL prior to vaccination.
Immuno subset=subjects from selected sites (N≥1000, at least 250 per region)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Concentrations (GMCs) Against HPV-18 Antibody in the Immunogenicity Subset.</measure>
    <time_frame>At pre-vaccination and at Month 7, 12, 18, 24, 36, 48, 60, 72 and 84</time_frame>
    <description>GMCs were expressed in ELISA units per milliliter (EL.U/mL).
Seronegative (Sero-) subjects are subjects who had an antibody concentration below 7 EL.U/mL prior to vaccination. Seropositive (Sero+) subjects are subjects who had an antibody concentration equal to or above 7 EL.U/mL prior to vaccination.
Immuno subset=subjects from selected sites (N≥1000, at least 250 per region)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Seroconverted Subjects Against HPV-16 and HPV-18 Viral Neutralization in a Selected Subset of Subjects.</measure>
    <time_frame>Prior to vaccination and at Months 7, 12, 18, 24, 48 and 84.</time_frame>
    <description>Seroconversion was defined as the appearance of antibodies (i.e.; titre greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination. HPV-16/18 assay cut-off value was defined as greater than or equal to 40 Estimated dose 50% (ED50). Sero- subjects are subjects who had an antibody concentration below 40 ED50 prior to vaccination. Sero+ subjects are subjects who had an antibody concentration equal to or above 50 ED50 prior to vaccination. ED50 = the estimated serum dilution reducing the signal generated by viral infection by 50%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMTs) Against HPV-16 and HPV-18 Viral Neutralization Antibodies in a Selected Subset of Subjects.</measure>
    <time_frame>Prior to vaccination and at Months 7, 12, 18, 24, 48 and 84.</time_frame>
    <description>Titers are expressed as geometric mean antibody titers (GMTs).
Seronegative (Sero-) subjects are subjects who had an antibody titer below 40 ED50 prior to vaccination. Seropositive (Sero+) subjects are subjects who had an antibody titer equal to or above 40 ED50 prior to vaccination.
ED50 = Estimated dose 50%, the estimated serum dilution reducing the signal generated by viral infection by 50%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms.</measure>
    <time_frame>Within 7 days (Days 0-6) after vaccination</time_frame>
    <description>Solicited local symptoms assessed were pain, redness and swelling. Any was defined as any solicited local symptom reported irrespective of intensity. Grade 3 pain was defined as pain that prevented normal activity. Grade 3 redness and swelling was defined as redness/swelling above 50 millimeter (mm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms.</measure>
    <time_frame>Within 7 days (Days 0-6) after vaccination</time_frame>
    <description>Solicited general symptoms assessed were arthralgia, fatigue, gastrointestinal, headache, myalgia, rash, urticaria and fever (Fever = axillary temperature above 37.5 degrees Celsius (°C)). Any = any solicited general symptom reported irrespective of intensity and relationship to vaccination. Related = symptoms considered by the investigator to have a causal relationship to vaccination. Grade 3 symptoms = symptoms that prevented normal activity. Grade 3 urticaria = urticaria distributed on at least 4 body areas. Grade 3 fever = axillary temperature above 39.0°C.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs).</measure>
    <time_frame>Within 30 days (Days 0 - 29) post-vaccination period.</time_frame>
    <description>An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Grade 3 unsolicited AE = an event that prevented normal activity.
A related AE = event assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs).</measure>
    <time_frame>Up to Month 48 and up to Month 84</time_frame>
    <description>SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects. A related SAE was defined as an event assessed by the investigator as causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Related or Fatal Serious Adverse Event.</measure>
    <time_frame>Up to Month 84</time_frame>
    <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Any AE/SAE Leading to Premature Discontinuation of the Study.</measure>
    <time_frame>Up to Month 84</time_frame>
    <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting New Onset of Chronic Disease (NOCDs).</measure>
    <time_frame>Up to Month 48</time_frame>
    <description>NOCDs include autoimmune disorders, asthma and type I diabetes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting New Onset of Autoimmune Disease (NOADs).</measure>
    <time_frame>Up to Month 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Reporting Medically Significant Conditions (MAEs).</measure>
    <time_frame>Up to Month 48</time_frame>
    <description>Medically significant conditions were defined as: AEs prompting emergency room or physician visits that were not (1) related to common diseases or (2) routine visits for physical examination or vaccination, or SAEs that were not related to common diseases. Common diseases included: upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervicovaginal yeast infections, menstrual cycle abnormalities and injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Pregnancies and Their Outcomes.</measure>
    <time_frame>Up to Month 48</time_frame>
    <description>Pregnancy outcomes are live infant, premature live infant, elective termination, ectopic pregnancy, spontaneous abortion, lost to follow-up and pregnancy ongoing. For each category it was specified if the infant presents congenital anomaly (CA) or no apparent congenital anomaly (No ACA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Using the Type Assignment Algorithm (TAA)</measure>
    <time_frame>Up to Month 48</time_frame>
    <description>CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.
Detection was done on subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.
TAA: Type assignment algorithm. The lesion was assigned to an HPV type found in the lesion if
the same HPV type was found in at least one of the two (closest) preceding cytology samples, or
none of the HPV types found in the lesion were found in any of the two preceding cytology samples (isolate HPV types)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18</measure>
    <time_frame>Up to Month 84</time_frame>
    <description>Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type(s) by PCR in cervical samples at 2 consecutive evaluations over approximately a 6-month interval. Detection was done in: - DNA- and sero-/+: subjects HPV DNA negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by ELISA at baseline (Month 0). - Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Persistent Infection (12-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18</measure>
    <time_frame>Up to Month 84</time_frame>
    <description>Persistent cervical HPV infection (12-month definition) was defined as the detection of the same HPV type(s) PCR in cervical samples at all available time points over approximately a 12-month interval (evaluations are planned at approximately 6-month intervals). - DNA- and sero-/+: subjects HPV DNA negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by ELISA at baseline (Month 0). - Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Persistent Infection (6-month Definition) With Oncogenic HPV Types Individually or in Combinations.</measure>
    <time_frame>Up to Month 84</time_frame>
    <description>Persistent cervical HPV infection (6-month definition) = detection of the same HPV type(s) by PCR in cervical samples at 2 consecutive evaluations over approximately a 6-month interval. Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. Detection was done in subjects HPV DNA- for the corresponding HPV type at baseline (at month 0 and Month 6) regardless of initial serostatus. HPV-HRW=All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18. HPV-HR=High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Persistent Infection (12-month Definition) With Oncogenic HPV Types Individually or in Combinations.</measure>
    <time_frame>Up to Month 84</time_frame>
    <description>Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. subjects HPV DNA- for the corresponding HPV type at Month 0 6, regardless of initial serostatus. HPV-HRW=All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18 HPV-HR=High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 , 68</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With HPV-16 and/or -18 Cervical Infection Detected Within the Lesional Component of the Cervical Tissue Specimen</measure>
    <time_frame>Up to Month 84</time_frame>
    <description>CIN2+ was defined as CIN grades 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer. Detection was done in: - DNA- and sero-: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative (sero-) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0). - Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline. Note: Results for seropositive status were not analysed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Within the Lesional Component of the Cervical Tissue Specimen</measure>
    <time_frame>Up to Month 84</time_frame>
    <description>CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer. Detection was done in: - DNA- and sero-/+: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0). - Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Within the Lesional Component of the Cervical Tissue Specimen</measure>
    <time_frame>Up to Month 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Irrespective of HPV Cervical Infection and Irrespective of Baseline HPV DNA Status</measure>
    <time_frame>Up to Month 84</time_frame>
    <description>CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer. Detection was done on all subjects irrespective of their baseline HPV DNA status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Any Cytological Abnormalities Associated With HPV-16 or HPV-18 Cervical Infection</measure>
    <time_frame>Up to Month 84</time_frame>
    <description>Cytological abnormalities = atypical squamous cells of undetermined significance (ASC-US). Detection was done in: - DNA- and sero-: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative (sero-) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0). - Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline. Results for seropositive status were not analysed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Cytological Abnormalities Associated With Oncogenic HPV Types Individually or in Combinations</measure>
    <time_frame>Up to Month 48</time_frame>
    <description>Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. Detection was done in subjects who were HPV DNA negative for the corresponding HPV type at baseline (at month 0 and Month 6) regardless of initial serostatus. HRW-HPV= All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18 HPV-HR= High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Histopathologically Confirmed Reduction of Local Cervical Therapy</measure>
    <time_frame>Up to Month 84</time_frame>
    <description>Detection was done on all subjects irrespective of their baseline HPV DNA status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With First Colposcopy</measure>
    <time_frame>Up to Month 84</time_frame>
    <description>Detection was done on all subjects irrespective of their baseline HPV DNA status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18 and/or With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection</measure>
    <time_frame>Up to Month 84</time_frame>
    <description>Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type(s) by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval. CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer. Detection was done on all subjects irrespective of their baseline HPV DNA and serostatus.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 or HPV-18 and/or With Histopathologically-confirmed CIN1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Using the HPV Type Assignment Algorithm (TAA).</measure>
    <time_frame>Up to Month 84</time_frame>
    <description>Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type(s) by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval. Detection was done on all subjects irrespective of their baseline HPV DNA and serostatus. The lesion was assigned to an HPV type found in the lesion if (1) the same HPV type was found in at least 1 of the 2 (closest) preceding cytology samples, or (2) none of the HPV types found in the lesion were found in any of the 2 preceding cytology samples (isolate HPV types)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5752</enrollment>
  <condition>Infections, Papillomavirus</condition>
  <arm_group>
    <arm_group_label>Cervarix Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aluminium Hydroxide Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cervarix</intervention_name>
    <description>Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.</description>
    <arm_group_label>Cervarix Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo control</intervention_name>
    <description>Subjects were planned to receive three doses of the control vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.</description>
    <arm_group_label>Aluminium Hydroxide Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  A woman who the investigator believes that she can and will comply with the
             requirements of the protocol.

          -  A women of at least 26 years of age at the time of the first vaccination.

          -  Written informed consent obtained from the subject prior to enrolment.

          -  Free of obvious health problems as established by medical history and clinical
             examination before entering into the study.

          -  Subject must have intact cervix.

          -  Subject must have a negative urine pregnancy test. This test is not applicable to
             women of non-childbearing potential.

          -  Subject must be of non-childbearing potential or, if of childbearing potential, she
             must be abstinent or must be using an effective method of birth control for 30 days
             prior to the first vaccination and must agree to continue such precautions for two
             months after completion of the vaccination series.

        Exclusion criteria:

          -  Pregnant or breastfeeding (women must be at least three months post-pregnancy and not
             breastfeeding to enter the study).

          -  A women planning to become pregnant, likely to become pregnant (as determined by the
             investigator) or planning to discontinue contraceptive precautions during the
             vaccination phase of the study, i.e. up to two months after the last vaccine dose
             (Month 0 - 8).

          -  Use of any investigational or non-registered product (drug or vaccine) other than the
             study vaccine within 30 days preceding the first dose of study vaccine, or planned use
             during the study period (up to Month 84).

          -  Chronic administration of immunosuppressants or other immune-modifying drugs within
             six months prior to the first vaccine dose.

          -  Planned administration/administration of a vaccine not foreseen by the study protocol
             within 30 days before and 30 days after (i.e. days 0 - 29) the first dose of study
             vaccine. Planned administration/administration of routine vaccines up to 8 days before
             the first dose of study vaccine is allowed. Enrolment will be deferred until the
             subject is outside of specified window.

          -  Previous administration of components of the investigational vaccine

          -  Previous vaccination against HPV or planned administration of any HPV vaccine other
             than that foreseen by the study protocol during the study period.

          -  History of HPV infection/treatment or planned treatment to evaluate an abnormal
             cervical cytology (Pap smear) test, e.g. colposcopy.

          -  Any medically diagnosed or suspected immunodeficient condition based on medical
             history and physical examination.

          -  History of allergic disease, suspected allergy or reactions likely to be exacerbated
             by any component of the study vaccine.

          -  Hypersensitivity to latex.

          -  Known acute or chronic, clinically significant neurologic, hepatic or renal functional
             abnormality, as determined by previous physical examination or laboratory tests.

          -  History of chronic condition(s) requiring treatment.

          -  Administration of immunoglobulins and/or any blood product within three months
             preceding the first dose of study vaccine, or planned administration during the study
             period. Enrolment will be deferred until the subject is outside of specified window.

          -  Acute disease at the time of enrolment.

          -  Heavy bleeding (menstruation or other) or heavy vaginal discharge in which a pelvic
             exam cannot be performed (and no cervical sample can be taken). Enrolment will be
             deferred until condition is resolved according to investigators medical judgement.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>26 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chaska</city>
        <state>Minnesota</state>
        <zip>55318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44311</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Carnegie</city>
        <state>Pennsylvania</state>
        <zip>15106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <zip>16508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wexford</city>
        <state>Pennsylvania</state>
        <zip>15090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>South Jordan</city>
        <state>Utah</state>
        <zip>84095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Crosse</city>
        <state>Wisconsin</state>
        <zip>54601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hobart</city>
        <state>Tasmania</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Truro</city>
        <state>Nova Scotia</state>
        <zip>B2N 1L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2L 6H6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 1Z1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1S 2L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cuenavaca</city>
        <state>Morelos</state>
        <zip>62430</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jojutla / Morelos</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1007 MB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Delft</city>
        <zip>2625 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Laguna</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Pablo City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taft Avenue, Manila</city>
        <zip>1700</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Almada</city>
        <zip>2805-267 Almada</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075 Coimbra</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1200-831 Lisboa</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Porto</city>
        <zip>4200-023 Porto</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Setúbal</city>
        <zip>2910-446 Setúbal</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620073</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>109263</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>115 478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sankt-Petersburg</city>
        <zip>190020</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sankt-Petersburg</city>
        <zip>199034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Singapore</city>
        <zip>229899</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Northwood</city>
        <state>Middlesex</state>
        <zip>HA6 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 7ZD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gateshead</city>
        <zip>NE9 6SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>EC1M 6BQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Thailand</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
  </removed_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2006</study_first_submitted>
  <study_first_submitted_qc>February 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2006</study_first_posted>
  <results_first_submitted>December 8, 2011</results_first_submitted>
  <results_first_submitted_qc>February 23, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 27, 2012</results_first_posted>
  <last_update_submitted>September 22, 2016</last_update_submitted>
  <last_update_submitted_qc>September 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccine</keyword>
  <keyword>Human papillomavirus</keyword>
  <keyword>Cervical Cancer</keyword>
  <keyword>Cervical Infection</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Aluminum Hydroxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>104820</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104820</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104820</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104820</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104820</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>104820</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Some subjects completed the study at Months 36 and 48 as they did not want to participate to the extensions up to Month 84, but they were included in the safety analysis for these subsequent timepoints.</recruitment_details>
      <pre_assignment_details>Enrolment was stratified by (1) age, with the majority of subjects in age strata 26 – 35 years and 36 – 45 years (about 45% each) and about 10% in the age stratum 46+ years, and (2) previous HPV history (in each age stratum, the number of women with a history of HPV infection/treatment was limited to approximately 15%).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cervarix Group</title>
          <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
        </group>
        <group group_id="P2">
          <title>Aluminium Hydroxide Group</title>
          <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Month 48</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2881"/>
                <participants group_id="P2" count="2871"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participated up to Month 48</title>
              <participants_list>
                <participants group_id="P1" count="2305"/>
                <participants group_id="P2" count="2281"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2456"/>
                <participants group_id="P2" count="2438"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="425"/>
                <participants group_id="P2" count="433"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="111"/>
                <participants group_id="P2" count="115"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="272"/>
                <participants group_id="P2" count="287"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Month 84</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2877"/>
                <participants group_id="P2" count="2870"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1904">The number of subjects who remained up to Month 48 in the Cervarix Group = 2146</participants>
                <participants group_id="P2" count="1881">The number of subjects who remained up to Month 48 in the Aluminium Hydroxide Group = 2116</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="973"/>
                <participants group_id="P2" count="989"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="187"/>
                <participants group_id="P2" count="190"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Absent Cervix</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Work related reasons</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Center closed, subject did not transfer</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Family problems</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of time</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Personal reason</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject does not want male physician</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Transport reimbursement delayed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to reach study site</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Under investigation locally</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Visit missed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No consent for Month 84 Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="731"/>
                <participants group_id="P2" count="754"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cervarix Group</title>
          <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
        </group>
        <group group_id="B2">
          <title>Aluminium Hydroxide Group</title>
          <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2881"/>
            <count group_id="B2" value="2871"/>
            <count group_id="B3" value="5752"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.0" spread="7.24"/>
                    <measurement group_id="B2" value="37.0" spread="7.32"/>
                    <measurement group_id="B3" value="37.0" spread="7.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Subjects</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2881"/>
                    <measurement group_id="B2" value="2871"/>
                    <measurement group_id="B3" value="5752"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18 and/or With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection.</title>
        <description>CIN1+ = CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.
Persistent HPV infection = detection of the same HPV type(s) by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.
DNA- and sero-/+: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and 6 and seronegative/positive (sero-/+) at Month 0 for the corresponding HPV-type by Enzyme-linked Immunosorbent Assay (ELISA)
Overall: subjects DNA- at Month 0 and 6 for the corresponding HPV-type, regardless of initial serostatus</description>
        <time_frame>Up to Month 48</time_frame>
        <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18 and/or With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection.</title>
          <description>CIN1+ = CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.
Persistent HPV infection = detection of the same HPV type(s) by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.
DNA- and sero-/+: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and 6 and seronegative/positive (sero-/+) at Month 0 for the corresponding HPV-type by Enzyme-linked Immunosorbent Assay (ELISA)
Overall: subjects DNA- at Month 0 and 6 for the corresponding HPV-type, regardless of initial serostatus</description>
          <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2224"/>
                <count group_id="O2" value="2190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16/18, DNA- and sero- subjects (N= 1898;1854)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, DNA- and sero- subjects (N=1545;1521)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, DNA- and sero- subjects (N=1597;1571)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16/18, DNA- and sero+ subjects (N=900;864)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, DNA- and sero+ subjects (N=605;594)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, DNA- and sero+ subjects (N=574;550)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16/18, overall (N=2224;2190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, overall (N=2167;2131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, overall (N=2203;2165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 or HPV-18 and/or With Histopathologically-CIN1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Using the HPV Type Assignment Algorithm (TAA).</title>
        <description>CIN1+ = CIN grades 1, 2 and 3, AIS and invasive cervical cancer. Persistent cervical HPV infection (6-month definition) = detection of the same HPV type(s) by PCR in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.
DNA- and sero-/+: subjects HPV DNA negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by ELISA at baseline (Month 0).
Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
        <time_frame>Up to Month 48</time_frame>
        <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 or HPV-18 and/or With Histopathologically-CIN1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Using the HPV Type Assignment Algorithm (TAA).</title>
          <description>CIN1+ = CIN grades 1, 2 and 3, AIS and invasive cervical cancer. Persistent cervical HPV infection (6-month definition) = detection of the same HPV type(s) by PCR in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.
DNA- and sero-/+: subjects HPV DNA negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by ELISA at baseline (Month 0).
Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
          <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2224"/>
                <count group_id="O2" value="2190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16/18, DNA- and sero- subjects (N=1898;1854)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, DNA- and sero- subjects (N=1545;1521)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, DNA- and sero- subjects (N=1597;1571)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16/18, DNA- and sero+ subjects (N=900;864)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, DNA- and sero+ subjects (N=605;594)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, DNA- and sero+ subjects (N=574;550)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16/18, overall (N=2224;2190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, overall (N=2167;2131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, overall (N=2203;2165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18 and/or With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection.</title>
        <description>CIN1+ = CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer. Persistent HPV infection = detection of the same HPV type(s) by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval. - DNA- and sero-/+: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and 6 and seronegative/positive (sero-/+) at Month 0 for the corresponding HPV-type by Enzyme-linked Immunosorbent Assay (ELISA) - Overall: subjects DNA- at Month 0 and 6 for the corresponding HPV-type, regardless of initial serostatus</description>
        <time_frame>Up to Month 84</time_frame>
        <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18 and/or With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection.</title>
          <description>CIN1+ = CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer. Persistent HPV infection = detection of the same HPV type(s) by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval. - DNA- and sero-/+: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and 6 and seronegative/positive (sero-/+) at Month 0 for the corresponding HPV-type by Enzyme-linked Immunosorbent Assay (ELISA) - Overall: subjects DNA- at Month 0 and 6 for the corresponding HPV-type, regardless of initial serostatus</description>
          <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2168"/>
                <count group_id="O2" value="2147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16/18, DNA- and sero- subjects (N= 1852;1818)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, DNA- and sero- subjects (N=1507;1491)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, DNA- and sero- subjects (N=1565;1541)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16/18, DNA- and sero+ subjects (N=870;849)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, DNA- and sero+ subjects (N=588;584)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, DNA- and sero+ subjects (N=552;540)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16/18, overall (N=2168;2147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, overall (N=2112;2091)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, overall (N=2149;2123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 or HPV-18 and/or With Histopathologically-CIN1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Using the HPV Type Assignment Algorithm (TAA).</title>
        <description>CIN1+ = CIN grades 1, 2 and 3, AIS and invasive cervical cancer. Persistent cervical HPV infection (6-month definition) = detection of the same HPV type(s) by PCR in cervical samples at 2 consecutive evaluations over approximately a 6-month interval. - DNA- and sero-/+: subjects HPV DNA negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by ELISA at baseline (Month 0). - Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
        <time_frame>Up to Month 84</time_frame>
        <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 or HPV-18 and/or With Histopathologically-CIN1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Using the HPV Type Assignment Algorithm (TAA).</title>
          <description>CIN1+ = CIN grades 1, 2 and 3, AIS and invasive cervical cancer. Persistent cervical HPV infection (6-month definition) = detection of the same HPV type(s) by PCR in cervical samples at 2 consecutive evaluations over approximately a 6-month interval. - DNA- and sero-/+: subjects HPV DNA negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by ELISA at baseline (Month 0). - Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
          <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2168"/>
                <count group_id="O2" value="2147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16/18, DNA- and sero- subjects (N=1852;1818)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, DNA- and sero- subjects (N=1507;1491)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, DNA- and sero- subjects (N=1565;1541)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16/18, DNA- and sero+ subjects (N=870;849)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, DNA- and sero+ subjects (N=588;584)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, DNA- and sero+ subjects (N=552;540)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16/18, overall (N=2168;2147)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, overall (N=2112;2091)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, overall (N=2149;2123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18</title>
        <description>Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type(s) by PCR in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.
Detection was done in:
DNA- and sero-/+: subjects HPV DNA negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by ELISA at baseline (Month 0).
Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
        <time_frame>Up to Month 48</time_frame>
        <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18</title>
          <description>Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type(s) by PCR in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.
Detection was done in:
DNA- and sero-/+: subjects HPV DNA negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by ELISA at baseline (Month 0).
Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
          <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2178"/>
                <count group_id="O2" value="2152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16/18, DNA- and sero- subjects (N=1859;1822)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, DNA- and sero- subjects (N=1518;1495)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, DNA- and sero- subjects (N=1566;1542)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16/18, DNA- and sero+ subjects (N=880;851)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, DNA- and sero+ subjects (N=591;583)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, DNA- and sero+ subjects (N=562;543)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16/18, overall (N=2178;2152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, overall (N=2126;2094)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, overall (N=2160;2127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Persistent Infection (12-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18</title>
        <description>Persistent cervical HPV infection (12-month definition) was defined as the detection of the same HPV type(s) PCR in cervical samples at all available time points over approximately a 12-month interval (evaluations are planned at approximately 6-month intervals).
DNA- and sero-/+: subjects HPV DNA negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by ELISA at baseline (Month 0).
Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
        <time_frame>Up to Month 48</time_frame>
        <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Persistent Infection (12-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18</title>
          <description>Persistent cervical HPV infection (12-month definition) was defined as the detection of the same HPV type(s) PCR in cervical samples at all available time points over approximately a 12-month interval (evaluations are planned at approximately 6-month intervals).
DNA- and sero-/+: subjects HPV DNA negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by ELISA at baseline (Month 0).
Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
          <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2146"/>
                <count group_id="O2" value="2124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16/18, DNA- and sero- subjects (N=1832;1800)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, DNA- and sero- subjects (N=1499;1476)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, DNA- and sero- subjects (N=1543;1525)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16/18, DNA- and sero+ subjects (N=864;839)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, DNA- and sero+ subjects (N=579;577)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, DNA- and sero+ subjects (N=553;532)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16/18, overall (N=2146;2124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, overall (N=2095;2069)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, overall (N=2128;2099)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Persistent Infection (6-month Definition) With Oncogenic HPV Types Individually or in Combinations.</title>
        <description>Persistent cervical HPV infection (6-month definition) = detection of the same HPV type(s) by PCR in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.
Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
Detection was done in subjects HPV DNA- for the corresponding HPV type at baseline (at month 0 and Month 6) regardless of initial serostatus.
HPV-HRW=All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18. HPV-HR=High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.</description>
        <time_frame>Up to Month 48</time_frame>
        <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Persistent Infection (6-month Definition) With Oncogenic HPV Types Individually or in Combinations.</title>
          <description>Persistent cervical HPV infection (6-month definition) = detection of the same HPV type(s) by PCR in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.
Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
Detection was done in subjects HPV DNA- for the corresponding HPV type at baseline (at month 0 and Month 6) regardless of initial serostatus.
HPV-HRW=All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18. HPV-HR=High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.</description>
          <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2179"/>
                <count group_id="O2" value="2154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16 (N=2126;2094)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 (N=2160;2127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31 (N=2126;2132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-33 (N=2158;2136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-35 (N=2165;2144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-39 (N=2150;2119)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-45 (N=2160;2130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-51 (N=2125;2113)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-52 (N=2113;2101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-56 (N=2154;2123)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-58 (N=2152;2135)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-59 (N=2158;2126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-66 (N=2141;2122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-68 (N=2138;2128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31/45 (N=2175;2152)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31/45/33/52/58 (N=2179;2154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-39/45/59/68 (N=2179;2154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31/33/35/52/58 (N=2179;2154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31/45/33/52/58/35/39/51/56/59 (N=2179;2154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-HRW (N=2179;2154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163"/>
                    <measurement group_id="O2" value="185"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-HR (N=2179;2154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170"/>
                    <measurement group_id="O2" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Persistent Infection (12-month Definition) With Oncogenic HPV Types Individually or in Combinations.</title>
        <description>Persistent HPV infection (12-month definition) = detection of the same HPV type(s) by PCR in cervical samples at available time points over approximately a 12-month interval (evaluations are planned at approximately 6-month intervals).
Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
subjects HPV DNA- for the corresponding HPV type at Month 0 6, regardless of initial serostatus.
HPV-HRW=All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18 HPV-HR=High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 , 68</description>
        <time_frame>Up to Month 48</time_frame>
        <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Persistent Infection (12-month Definition) With Oncogenic HPV Types Individually or in Combinations.</title>
          <description>Persistent HPV infection (12-month definition) = detection of the same HPV type(s) by PCR in cervical samples at available time points over approximately a 12-month interval (evaluations are planned at approximately 6-month intervals).
Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
subjects HPV DNA- for the corresponding HPV type at Month 0 6, regardless of initial serostatus.
HPV-HRW=All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18 HPV-HR=High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 , 68</description>
          <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2147"/>
                <count group_id="O2" value="2126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16 (N=2095;2069)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 (N=2128;2099)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31 (N=2096;2104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-33 (N=2126;2110)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-35 (N=2133;2116)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-39 (N=2119;2091)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-45 (N=2129;2102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-51 (N=2093;2086)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-52 (N=2081;2074)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-56 (N=2124;2096)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-58 (N=2120;2108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-59 (N=2126;2098)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-66 (N=2109;2094)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-68 (N=2106;2100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31/45 (N=2144;2124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31/45/33/52/58 (N=2147;2126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-39/45/59/68 (N=2147;2126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31/33/35/52/58 (N=2147;2126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31/45/33/52/58/35/39/51/56/59 (N=2147;2126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-HRW (N=2147;2126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-HR (N=2147;2126)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With HPV-16 and/or -18 Cervical Infection Detected Within the Lesional Component of the Cervical Tissue Specimen</title>
        <description>CIN2+ was defined as CIN grades 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.
Detection was done in:
DNA- and sero-: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative (sero-) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0).
Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.
Note: Results for seropositive status were not analysed.</description>
        <time_frame>Up to Month 48</time_frame>
        <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With HPV-16 and/or -18 Cervical Infection Detected Within the Lesional Component of the Cervical Tissue Specimen</title>
          <description>CIN2+ was defined as CIN grades 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.
Detection was done in:
DNA- and sero-: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative (sero-) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0).
Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.
Note: Results for seropositive status were not analysed.</description>
          <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2224"/>
                <count group_id="O2" value="2190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16/18, DNA- and sero- subjects (N=1898;1854)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, DNA- and sero- subjects (N=1545;1521)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, DNA- and sero- subjects (N=1597;1571)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16/18, overall (N=2224;2190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, overall (N=2167;2131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, overall (N=2203;2165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Within the Lesional Component of the Cervical Tissue Specimen</title>
        <description>CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.
Detection was done in:
DNA- and sero-/+: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0).
Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
        <time_frame>Up to Month 48</time_frame>
        <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Within the Lesional Component of the Cervical Tissue Specimen</title>
          <description>CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.
Detection was done in:
DNA- and sero-/+: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0).
Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
          <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2224"/>
                <count group_id="O2" value="2190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16/18, DNA- and sero- subjects (N=1898;1854)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, DNA- and sero- subjects (N=1545;1521)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, DNA- and sero- subjects (N=1597;1571)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16/18, DNA- and sero+ subjects (N=900;864)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, DNA- and sero+ subjects (N=605;594)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, DNA- and sero+ subjects (N=574;550)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16/18, overall (N=2224;2190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, overall (N=2167;2131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, overall (N=2203;2165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Within the Lesional Component of the Cervical Tissue Specimen</title>
        <description>CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.
Detection was done on all subjects irrespective of their baseline HPV DNA and serostatus.</description>
        <time_frame>Up to Month 48</time_frame>
        <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Within the Lesional Component of the Cervical Tissue Specimen</title>
          <description>CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.
Detection was done on all subjects irrespective of their baseline HPV DNA and serostatus.</description>
          <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2740"/>
                <count group_id="O2" value="2737"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16/18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Irrespective of HPV Cervical Infection and Irrespective of Baseline HPV DNA Status</title>
        <description>CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.
Detection was done on all subjects irrespective of their baseline HPV DNA status.</description>
        <time_frame>Up to Month 48</time_frame>
        <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Irrespective of HPV Cervical Infection and Irrespective of Baseline HPV DNA Status</title>
          <description>CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.
Detection was done on all subjects irrespective of their baseline HPV DNA status.</description>
          <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2740"/>
                <count group_id="O2" value="2737"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="152"/>
                    <measurement group_id="O2" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Cytological Abnormalities Associated With HPV-16 or HPV-18 Cervical Infection</title>
        <description>Cytological abnormalities = atypical squamous cells of undetermined significance (ASC-US).
Detection was done in:
DNA- and sero-: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative (sero-) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0).
Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.
Results for seropositive status were not analysed.</description>
        <time_frame>Up to Month 48</time_frame>
        <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Cytological Abnormalities Associated With HPV-16 or HPV-18 Cervical Infection</title>
          <description>Cytological abnormalities = atypical squamous cells of undetermined significance (ASC-US).
Detection was done in:
DNA- and sero-: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative (sero-) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0).
Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.
Results for seropositive status were not analysed.</description>
          <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2224"/>
                <count group_id="O2" value="2190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16/18, DNA- and sero- subjects (N=1898;1854)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, DNA- and sero- subjects (N=1545;1521)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, DNA- and sero- subjects (N=1597;1571)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16/18, overall (N=2224;2190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 (N=2167;2131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 (N=2203;2165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Cytological Abnormalities Associated With Oncogenic HPV Types Individually or in Combinations</title>
        <description>Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
Detection was done in subjects who were HPV DNA negative for the corresponding HPV type at baseline (at month 0 and Month 6) regardless of initial serostatus.
HRW-HPV= All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18 HPV-HR= High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68</description>
        <time_frame>Up to Month 48</time_frame>
        <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Cytological Abnormalities Associated With Oncogenic HPV Types Individually or in Combinations</title>
          <description>Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.
Detection was done in subjects who were HPV DNA negative for the corresponding HPV type at baseline (at month 0 and Month 6) regardless of initial serostatus.
HRW-HPV= All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18 HPV-HR= High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68</description>
          <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2225"/>
                <count group_id="O2" value="2192"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16 (N=2167;2131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 (N=2203;2165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31 (N=2172;2170)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-33 (N=2204;2173)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-35 (N=2211;2181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-39 (N=2196;2156)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-45 (N=2206;2168)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-51 (N=2171;2149)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-52 (N=2158;2139)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-56 (N=2200;2158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-58 (N=2198;2172)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-59 (N=2202;2164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-66 (N=2187;2160)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-68 (N=2184;2164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31/45 (N=2221;2190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31/45/33/52/58 (N=2225;2192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-39/45/59/68 (N=2225;2192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31/33/35/52/58 (N=2225;2192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31/45/33/52/58/35/39/51/56/59 (N=2225;2192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-HRW (N=2225;2192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94"/>
                    <measurement group_id="O2" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-HR (N=2225;2192)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Histopathologically Confirmed Reduction of Local Cervical Therapy</title>
        <description>Detection was done on all subjects irrespective of their baseline HPV DNA status.</description>
        <time_frame>Up to Month 48</time_frame>
        <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Histopathologically Confirmed Reduction of Local Cervical Therapy</title>
          <description>Detection was done on all subjects irrespective of their baseline HPV DNA status.</description>
          <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2740"/>
                <count group_id="O2" value="2737"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With First Colposcopy</title>
        <description>Detection was done on all subjects irrespective of their baseline HPV DNA status.</description>
        <time_frame>Up to Month 48</time_frame>
        <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With First Colposcopy</title>
          <description>Detection was done on all subjects irrespective of their baseline HPV DNA status.</description>
          <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2741"/>
                <count group_id="O2" value="2738"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="392"/>
                    <measurement group_id="O2" value="422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18 and/or With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection</title>
        <description>Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type(s) by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.
CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.
Detection was done on all subjects irrespective of their baseline HPV DNA and serostatus.</description>
        <time_frame>Up to Month 48</time_frame>
        <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18 and/or With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection</title>
          <description>Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type(s) by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.
CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.
Detection was done on all subjects irrespective of their baseline HPV DNA and serostatus.</description>
          <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2772"/>
                <count group_id="O2" value="2779"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16/18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 or HPV-18 and/or With Histopathologically-confirmed CIN1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Using the HPV Type Assignment Algorithm (TAA).</title>
        <description>Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type(s) by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.
Detection was done on all subjects irrespective of their baseline HPV DNA and serostatus.
The lesion was assigned to an HPV type found in the lesion if (1) the same HPV type was found in at least 1 of the 2 (closest) preceding cytology samples, or (2) none of the HPV types found in the lesion were found in any of the 2 preceding cytology samples (isolate HPV types)</description>
        <time_frame>Up to Month 48</time_frame>
        <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 or HPV-18 and/or With Histopathologically-confirmed CIN1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Using the HPV Type Assignment Algorithm (TAA).</title>
          <description>Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type(s) by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval.
Detection was done on all subjects irrespective of their baseline HPV DNA and serostatus.
The lesion was assigned to an HPV type found in the lesion if (1) the same HPV type was found in at least 1 of the 2 (closest) preceding cytology samples, or (2) none of the HPV types found in the lesion were found in any of the 2 preceding cytology samples (isolate HPV types)</description>
          <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2772"/>
                <count group_id="O2" value="2779"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16/18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted Subjects Against HPV-16 in the Immunogenicity Subset.</title>
        <description>Seroconversion was defined as the appearance of antibodies (i.e.; titre greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.
HPV-16 assay cut-off value was defined as greater than or equal to 8 ELISA units per millilitre (EL.U/mL). Seronegative (Sero-) subjects are subjects who had an antibody concentration below 8 EL.U/mL prior to vaccination. Seropositive (Sero+) subjects are subjects who had an antibody concentration equal to or above 8 EL.U/mL prior to vaccination.
Immuno subset=subjects from selected sites N≥1000, at least 250 per region</description>
        <time_frame>At pre-vaccination and at Month 7, 12, 18, 24, 36, 48, 60, 72 and 84</time_frame>
        <population>The According-To-Protocol cohort for immunogenicity included subjects for whom immunogenicity data were available and for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination. The 15% subset of women enrolled with prior history of HPV disease/infection was included.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects Against HPV-16 in the Immunogenicity Subset.</title>
          <description>Seroconversion was defined as the appearance of antibodies (i.e.; titre greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.
HPV-16 assay cut-off value was defined as greater than or equal to 8 ELISA units per millilitre (EL.U/mL). Seronegative (Sero-) subjects are subjects who had an antibody concentration below 8 EL.U/mL prior to vaccination. Seropositive (Sero+) subjects are subjects who had an antibody concentration equal to or above 8 EL.U/mL prior to vaccination.
Immuno subset=subjects from selected sites N≥1000, at least 250 per region</description>
          <population>The According-To-Protocol cohort for immunogenicity included subjects for whom immunogenicity data were available and for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination. The 15% subset of women enrolled with prior history of HPV disease/infection was included.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="406"/>
                <count group_id="O2" value="374"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sero- before vaccination (N=406;374)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 7 (N=406;371)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="406"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 12 (N=384;349)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="384"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 18 (N=377;340)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="377"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 24 (N=392;350)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="392"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 36 (N=361;320)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="361"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 48 (N=345;316)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="345"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 60 (N=275;251)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="275"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 72 (N=277;260)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="276"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 84 (N=275;255)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="273"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ before vaccination (N=170;179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170"/>
                    <measurement group_id="O2" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 7 (N=170;179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="170"/>
                    <measurement group_id="O2" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 12 (N=154;158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 24 (N=158;165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 18 (N=147;154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 36 (N=137;146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 48 (N=132;145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132"/>
                    <measurement group_id="O2" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 60 (N=99,95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 72 (N=99,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 84 (N=95,101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted Subjects Against HPV-18 in the Immunogenicity Subset.</title>
        <description>Seroconversion was defined as the appearance of antibodies (i.e.; titre greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.
HPV-18 assay cut-off value was defined as greater than or equal to 7 ELISA units per millilitre (EL.U/mL). Seronegative (Sero-) subjects are subjects who had an antibody concentration below 7 EL.U/mL prior to vaccination. Seropositive (Sero+) subjects are subjects who had an antibody concentration equal to or above 7 EL.U/mL prior to vaccination.
Immuno subset=subjects from selected sites N≥1000, at least 250 per region</description>
        <time_frame>At pre-vaccination and at Month 7, 12, 18, 24, 36, 48, 60, 72 and 84</time_frame>
        <population>The According-To-Protocol cohort for immunogenicity included subjects for whom immunogenicity data were available and for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination. The 15% subset of women enrolled with prior history of HPV disease/infection was included.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects Against HPV-18 in the Immunogenicity Subset.</title>
          <description>Seroconversion was defined as the appearance of antibodies (i.e.; titre greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.
HPV-18 assay cut-off value was defined as greater than or equal to 7 ELISA units per millilitre (EL.U/mL). Seronegative (Sero-) subjects are subjects who had an antibody concentration below 7 EL.U/mL prior to vaccination. Seropositive (Sero+) subjects are subjects who had an antibody concentration equal to or above 7 EL.U/mL prior to vaccination.
Immuno subset=subjects from selected sites N≥1000, at least 250 per region</description>
          <population>The According-To-Protocol cohort for immunogenicity included subjects for whom immunogenicity data were available and for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination. The 15% subset of women enrolled with prior history of HPV disease/infection was included.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="405"/>
                <count group_id="O2" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sero- before vaccination (N=405;379)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 7 (N=405;374)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="405"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 12 (N=376;352)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="375"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 18 (N=366;347)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="366"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 24 (N=389;358)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="387"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 36 (N=348;328)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="346"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 48 (N=338;320)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="336"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 60 (N=268;246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="266"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 72 (N=269;254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at month 84 (N=268;248)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ before vaccination (N=163;164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163"/>
                    <measurement group_id="O2" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 7 (N=163;161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163"/>
                    <measurement group_id="O2" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 12 (N=154;144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 18 (N=149;141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 24 (N=153;150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153"/>
                    <measurement group_id="O2" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 36 (N=142;131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 48 (N=133;131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 60 (N=101;91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 72 (N=103;99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 84 (N=98;98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentrations (GMCs) Against HPV-16 Antibody in the Immunogenicity Subset.</title>
        <description>GMCs were expressed in ELISA units per milliliter (EL.U/mL).
Seronegative (Sero-) subjects are subjects who had an antibody concentration below 8 EL.U/mL prior to vaccination. Seropositive (Sero+) subjects are subjects who had an antibody concentration equal to or above 8 EL.U/mL prior to vaccination.
Immuno subset=subjects from selected sites (N≥1000, at least 250 per region)</description>
        <time_frame>At pre-vaccination and at Month 7, 12, 18, 24, 36, 48, 60, 72 and 84</time_frame>
        <population>The According-To-Protocol cohort for immunogenicity included subjects for whom immunogenicity data were available and for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination. The 15% subset of women enrolled with prior history of HPV disease/infection was included.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations (GMCs) Against HPV-16 Antibody in the Immunogenicity Subset.</title>
          <description>GMCs were expressed in ELISA units per milliliter (EL.U/mL).
Seronegative (Sero-) subjects are subjects who had an antibody concentration below 8 EL.U/mL prior to vaccination. Seropositive (Sero+) subjects are subjects who had an antibody concentration equal to or above 8 EL.U/mL prior to vaccination.
Immuno subset=subjects from selected sites (N≥1000, at least 250 per region)</description>
          <population>The According-To-Protocol cohort for immunogenicity included subjects for whom immunogenicity data were available and for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination. The 15% subset of women enrolled with prior history of HPV disease/infection was included.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="406"/>
                <count group_id="O2" value="374"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sero-before vaccination (N=406;374)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not calculable as no subject had HPV-16 antibody concentration equal to or above the assay cut-off value.</measurement>
                    <measurement group_id="O2" value="NA">Not calculable as no subject had HPV-16 antibody concentration equal to or above the assay cut-off value.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 7 (N=406;371)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5412.9" lower_limit="4934.3" upper_limit="5938.0"/>
                    <measurement group_id="O2" value="4.3" lower_limit="4.1" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 12 (N=384;349)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1542.5" lower_limit="1393.2" upper_limit="1707.8"/>
                    <measurement group_id="O2" value="4.4" lower_limit="4.2" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 18 (N=377;340)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="992.6" lower_limit="893.9" upper_limit="1102.2"/>
                    <measurement group_id="O2" value="4.1" lower_limit="4.0" upper_limit="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 24 (N=392;350)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="827.8" lower_limit="745.2" upper_limit="919.5"/>
                    <measurement group_id="O2" value="4.2" lower_limit="4.1" upper_limit="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 36 (N=361;320)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="612.9" lower_limit="550.1" upper_limit="682.8"/>
                    <measurement group_id="O2" value="4.5" lower_limit="4.2" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 48 (N=345;316)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="546.2" lower_limit="490.4" upper_limit="608.2"/>
                    <measurement group_id="O2" value="4.6" lower_limit="4.4" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 60 (N=275;251)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="447.1" lower_limit="394.3" upper_limit="507.0"/>
                    <measurement group_id="O2" value="4.3" lower_limit="4.1" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 72 (N=277;260)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="412.8" lower_limit="364.0" upper_limit="468.1"/>
                    <measurement group_id="O2" value="9.8" lower_limit="9.5" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 84 (N=275;255)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="381.0" lower_limit="334.7" upper_limit="433.8"/>
                    <measurement group_id="O2" value="9.6" lower_limit="9.4" upper_limit="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ before vaccination (N=170;179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.3" lower_limit="33.6" upper_limit="45.9"/>
                    <measurement group_id="O2" value="38.6" lower_limit="33.2" upper_limit="44.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 7 (N=170;179)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5845.5" lower_limit="5113.8" upper_limit="6682.0"/>
                    <measurement group_id="O2" value="33.4" lower_limit="28.2" upper_limit="39.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at month 12 (N=154;158)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2705.8" lower_limit="2313.2" upper_limit="3165.1"/>
                    <measurement group_id="O2" value="38.0" lower_limit="32.0" upper_limit="45.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 18 (N=147;154)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2104.7" lower_limit="1780.5" upper_limit="2487.8"/>
                    <measurement group_id="O2" value="30.5" lower_limit="25.2" upper_limit="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 24 (N=158;165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1883.5" lower_limit="1599.4" upper_limit="2218.1"/>
                    <measurement group_id="O2" value="29.6" lower_limit="24.5" upper_limit="35.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at month 36 (N=137;146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1363.8" lower_limit="1138.2" upper_limit="1634.2"/>
                    <measurement group_id="O2" value="30.6" lower_limit="25.3" upper_limit="37.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 48 (N=132;145)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1261.2" lower_limit="1048.4" upper_limit="1517.1"/>
                    <measurement group_id="O2" value="34.3" lower_limit="28.8" upper_limit="40.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 60 (N=99;95)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="943.0" lower_limit="749.2" upper_limit="1187.0"/>
                    <measurement group_id="O2" value="24.7" lower_limit="19.2" upper_limit="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 72 (N=99;102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1053.7" lower_limit="841.0" upper_limit="1320.3"/>
                    <measurement group_id="O2" value="25.6" lower_limit="20.7" upper_limit="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 84 (N=95;101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="954.3" lower_limit="755.3" upper_limit="1205.8"/>
                    <measurement group_id="O2" value="23.9" lower_limit="19.3" upper_limit="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Concentrations (GMCs) Against HPV-18 Antibody in the Immunogenicity Subset.</title>
        <description>GMCs were expressed in ELISA units per milliliter (EL.U/mL).
Seronegative (Sero-) subjects are subjects who had an antibody concentration below 7 EL.U/mL prior to vaccination. Seropositive (Sero+) subjects are subjects who had an antibody concentration equal to or above 7 EL.U/mL prior to vaccination.
Immuno subset=subjects from selected sites (N≥1000, at least 250 per region)</description>
        <time_frame>At pre-vaccination and at Month 7, 12, 18, 24, 36, 48, 60, 72 and 84</time_frame>
        <population>The According-To-Protocol cohort for immunogenicity included subjects for whom immunogenicity data were available and for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination. The 15% subset of women enrolled with prior history of HPV disease/infection was included.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentrations (GMCs) Against HPV-18 Antibody in the Immunogenicity Subset.</title>
          <description>GMCs were expressed in ELISA units per milliliter (EL.U/mL).
Seronegative (Sero-) subjects are subjects who had an antibody concentration below 7 EL.U/mL prior to vaccination. Seropositive (Sero+) subjects are subjects who had an antibody concentration equal to or above 7 EL.U/mL prior to vaccination.
Immuno subset=subjects from selected sites (N≥1000, at least 250 per region)</description>
          <population>The According-To-Protocol cohort for immunogenicity included subjects for whom immunogenicity data were available and for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination. The 15% subset of women enrolled with prior history of HPV disease/infection was included.</population>
          <units>EL.U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="405"/>
                <count group_id="O2" value="379"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sero- before vaccination (N=405;379)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not calculable as no subject had HPV-18 antibody concentration equal to or above the assay cut-off value.</measurement>
                    <measurement group_id="O2" value="NA">Not calculable as no subject had HPV-18 antibody concentration equal to or above the assay cut-off value.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 7 (N=405;374)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2567.7" lower_limit="2339.5" upper_limit="2818.2"/>
                    <measurement group_id="O2" value="3.7" lower_limit="3.6" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 12 (N=376;352)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="645.3" lower_limit="576.6" upper_limit="722.1"/>
                    <measurement group_id="O2" value="3.7" lower_limit="3.6" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 18 (N=366;347)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="402.6" lower_limit="359.7" upper_limit="450.6"/>
                    <measurement group_id="O2" value="3.7" lower_limit="3.6" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 24 (N=389;358)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="321.7" lower_limit="286.9" upper_limit="360.7"/>
                    <measurement group_id="O2" value="3.7" lower_limit="3.6" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 36 (N=348;328)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="245.9" lower_limit="218.5" upper_limit="276.8"/>
                    <measurement group_id="O2" value="3.7" lower_limit="3.6" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 48 (N=338;320)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="228.5" lower_limit="201.9" upper_limit="258.7"/>
                    <measurement group_id="O2" value="3.7" lower_limit="3.6" upper_limit="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 60 (N=268;246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174.3" lower_limit="151.2" upper_limit="200.8"/>
                    <measurement group_id="O2" value="3.8" lower_limit="3.6" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 72 (N=269;254)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177.7" lower_limit="154.1" upper_limit="204.8"/>
                    <measurement group_id="O2" value="9.2" lower_limit="9.0" upper_limit="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero- at Month 84 (N=268;248)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.2" lower_limit="143.4" upper_limit="192.7"/>
                    <measurement group_id="O2" value="9.1" lower_limit="9.0" upper_limit="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ before vaccination (N=163;164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0" lower_limit="19.9" upper_limit="26.7"/>
                    <measurement group_id="O2" value="24.2" lower_limit="20.6" upper_limit="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 7 (N=163;161)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2933.9" lower_limit="2557.1" upper_limit="3366.3"/>
                    <measurement group_id="O2" value="21.9" lower_limit="18.1" upper_limit="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 12 (N=154;144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="936.2" lower_limit="796.4" upper_limit="1100.4"/>
                    <measurement group_id="O2" value="23.6" lower_limit="19.4" upper_limit="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 18 (N=149;141)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="661.3" lower_limit="560.9" upper_limit="779.7"/>
                    <measurement group_id="O2" value="19.5" lower_limit="15.7" upper_limit="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 24 (N=153;150)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="573.6" lower_limit="487.7" upper_limit="674.6"/>
                    <measurement group_id="O2" value="16.6" lower_limit="13.5" upper_limit="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 36 (N=142;131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="423.1" lower_limit="357.9" upper_limit="500.1"/>
                    <measurement group_id="O2" value="16.4" lower_limit="12.9" upper_limit="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 48 (N=133;131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="392.3" lower_limit="328.9" upper_limit="468.0"/>
                    <measurement group_id="O2" value="15.9" lower_limit="12.7" upper_limit="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 60 (N=101;91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="306.0" lower_limit="245.7" upper_limit="380.9"/>
                    <measurement group_id="O2" value="12.9" lower_limit="9.8" upper_limit="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 72 (N=103;99)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="324.8" lower_limit="264.3" upper_limit="399.1"/>
                    <measurement group_id="O2" value="16.2" lower_limit="13.3" upper_limit="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sero+ at Month 84 (N=98;98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302.2" lower_limit="243.4" upper_limit="375.2"/>
                    <measurement group_id="O2" value="16.5" lower_limit="13.4" upper_limit="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Seroconverted Subjects Against HPV-16 and HPV-18 Viral Neutralization in a Selected Subset of Subjects.</title>
        <description>Seroconversion was defined as the appearance of antibodies (i.e.; titre greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination. HPV-16/18 assay cut-off value was defined as greater than or equal to 40 Estimated dose 50% (ED50). Sero- subjects are subjects who had an antibody concentration below 40 ED50 prior to vaccination. Sero+ subjects are subjects who had an antibody concentration equal to or above 50 ED50 prior to vaccination. ED50 = the estimated serum dilution reducing the signal generated by viral infection by 50%</description>
        <time_frame>Prior to vaccination and at Months 7, 12, 18, 24, 48 and 84.</time_frame>
        <population>The According-To-Protocol cohort for immunogenicity included subjects for whom immunogenicity data were available and for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination. The 15% subset of women enrolled with prior history of HPV disease/infection was included.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Seroconverted Subjects Against HPV-16 and HPV-18 Viral Neutralization in a Selected Subset of Subjects.</title>
          <description>Seroconversion was defined as the appearance of antibodies (i.e.; titre greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination. HPV-16/18 assay cut-off value was defined as greater than or equal to 40 Estimated dose 50% (ED50). Sero- subjects are subjects who had an antibody concentration below 40 ED50 prior to vaccination. Sero+ subjects are subjects who had an antibody concentration equal to or above 50 ED50 prior to vaccination. ED50 = the estimated serum dilution reducing the signal generated by viral infection by 50%</description>
          <population>The According-To-Protocol cohort for immunogenicity included subjects for whom immunogenicity data were available and for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination. The 15% subset of women enrolled with prior history of HPV disease/infection was included.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16 sero- [pre-vaccination] (N=37;37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 sero- [at Month 7] (N=37;37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 sero- [at Month 12] (N=37;37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 sero- [at Month 18] (N=36;37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 sero- [at Month 24] (N=35;37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 sero- [at Month 48] (N=27;33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 sero- [at Month 84] (N=20;25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 sero+ [pre-vaccination] (N=4;1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 sero+ [at Month 7] (N=4;1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 sero+ [at Month 12] (N=4;1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 sero+ [at Month 18] (N=4;1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 sero+ [at Month 24] (N=4;1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 sero+ [at Month 48] (N=3;1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 sero+ [at Month 84] (N=3;1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 sero- [pre-vaccination] (N=38;35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 sero- [at Month 7] (N=38;35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 sero- [at Month 12] (N=38;35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 sero- [at Month 18] (N=37;35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 sero- [at Month 24] (N=36;35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 sero- [at Month 48] (N=29;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 sero- [at Month 84] (N=22;25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 sero+ [pre-vaccination] (N=3;3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 sero+ [at Month 7] (N=3;3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 sero+ [at Month 12] (N=3;3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 sero+ [at Month 18] (N=3;3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 sero+ [at Month 24] (N=3;3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 sero+ [at Month 48] (N=1;2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 sero+ [at Month 84] (N=1;1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titers (GMTs) Against HPV-16 and HPV-18 Viral Neutralization Antibodies in a Selected Subset of Subjects.</title>
        <description>Titers are expressed as geometric mean antibody titers (GMTs).
Seronegative (Sero-) subjects are subjects who had an antibody titer below 40 ED50 prior to vaccination. Seropositive (Sero+) subjects are subjects who had an antibody titer equal to or above 40 ED50 prior to vaccination.
ED50 = Estimated dose 50%, the estimated serum dilution reducing the signal generated by viral infection by 50%</description>
        <time_frame>Prior to vaccination and at Months 7, 12, 18, 24, 48 and 84.</time_frame>
        <population>The According-To-Protocol cohort for immunogenicity included subjects for whom immunogenicity data were available and for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination. The 15% subset of women enrolled with prior history of HPV disease/infection was included.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) Against HPV-16 and HPV-18 Viral Neutralization Antibodies in a Selected Subset of Subjects.</title>
          <description>Titers are expressed as geometric mean antibody titers (GMTs).
Seronegative (Sero-) subjects are subjects who had an antibody titer below 40 ED50 prior to vaccination. Seropositive (Sero+) subjects are subjects who had an antibody titer equal to or above 40 ED50 prior to vaccination.
ED50 = Estimated dose 50%, the estimated serum dilution reducing the signal generated by viral infection by 50%</description>
          <population>The According-To-Protocol cohort for immunogenicity included subjects for whom immunogenicity data were available and for whom assay results were available for antibodies against at least 1 study vaccine antigen component after vaccination. The 15% subset of women enrolled with prior history of HPV disease/infection was included.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16 sero- [pre-vaccination] (N=37;37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not calculable as no subject had HPV-16 antibody titer equal to or above the assay cut-off value.</measurement>
                    <measurement group_id="O2" value="NA">Not calculable as no subject had HPV-16 antibody titer equal to or above the assay cut-off value.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 sero- [at Month 7] (N=37;37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11663.5" lower_limit="7507.2" upper_limit="18120.8"/>
                    <measurement group_id="O2" value="20.8" lower_limit="19.2" upper_limit="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 sero- [at Month 12] (N=37;37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5597.7" lower_limit="3688.3" upper_limit="8495.6"/>
                    <measurement group_id="O2" value="NA">Not calculable as no subject had HPV-16 antibody titer equal to or above the assay cut-off value.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 sero- [at Month 18] (N=36;37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2175.2" lower_limit="1390.8" upper_limit="3401.9"/>
                    <measurement group_id="O2" value="NA">Not calculable as no subject had HPV-16 antibody titer equal to or above the assay cut-off value.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 sero- [at Month 24] (N=35;37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1941.7" lower_limit="1193.0" upper_limit="3160.4"/>
                    <measurement group_id="O2" value="22.3" lower_limit="18.6" upper_limit="26.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 sero- [at Month 48] (N=27;33)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="828.9" lower_limit="488.4" upper_limit="1406.7"/>
                    <measurement group_id="O2" value="21.4" lower_limit="18.7" upper_limit="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 sero- [at Month 84] (N=20;25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1213.4" lower_limit="529.8" upper_limit="2779.1"/>
                    <measurement group_id="O2" value="NA">Not calculable as no subject had HPV-16 antibody titer equal to or above the assay cut-off value.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 sero+ [pre-vaccination] (N=4;1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139.3" lower_limit="32.7" upper_limit="594.2"/>
                    <measurement group_id="O2" value="45.0">Data were not calculable because of too few subjects.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 sero+ [at Month 7] (N=4;1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20283.2" lower_limit="2428.3" upper_limit="169422.0"/>
                    <measurement group_id="O2" value="107.0">Data were not calculable because of too few subjects.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 sero+ [at Month 12] (N=4;1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19484.3" lower_limit="7049.3" upper_limit="53854.2"/>
                    <measurement group_id="O2" value="99.0">Data were not calculable because of too few subjects.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 sero+ [at Month 18] (N=4;1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4393.3" lower_limit="798.4" upper_limit="24175.0"/>
                    <measurement group_id="O2" value="93.0">Data were not calculable because of too few subjects.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 sero+ [at Month 24] (N=4;1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9459.1" lower_limit="2168.4" upper_limit="41263.7"/>
                    <measurement group_id="O2" value="NA">Not calculable as no subject had HPV-16 antibody titer equal to or above the assay cut-off value.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 sero+ [at Month 48] (N=3;1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4187.2" lower_limit="676.4" upper_limit="25921.6"/>
                    <measurement group_id="O2" value="NA">Not calculable as no subject had HPV-16 antibody titer equal to or above the assay cut-off value.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 sero+ [at Month 84] (N=3;1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5837.0" lower_limit="963.7" upper_limit="35354.6"/>
                    <measurement group_id="O2" value="NA">Not calculable as no subject had HPV-16 antibody titer equal to or above the assay cut-off value.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 sero- [pre-vaccination] (N=38;35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Not calculable as no subject had HPV-18 antibody titer equal to or above the assay cut-off value.</measurement>
                    <measurement group_id="O2" value="NA">Not calculable as no subject had HPV-18 antibody titer equal to or above the assay cut-off value.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 sero- [at Month 7] (N=38;35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7959.6" lower_limit="4648.0" upper_limit="13630.7"/>
                    <measurement group_id="O2" value="NA">Not calculable as no subject had HPV-18 antibody titer equal to or above the assay cut-off value.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 sero- [at Month 12] (N=38;35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1979.9" lower_limit="1201.6" upper_limit="3262.5"/>
                    <measurement group_id="O2" value="NA">Not calculable as no subject had HPV-18 antibody titer equal to or above the assay cut-off value.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 sero- [at Month 18] (N=37;35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1334.6" lower_limit="793.3" upper_limit="2245.3"/>
                    <measurement group_id="O2" value="NA">Not calculable as no subject had HPV-18 antibody titer equal to or above the assay cut-off value.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 sero- [at Month 24] (N=36;35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="826.6" lower_limit="493.6" upper_limit="1384.1"/>
                    <measurement group_id="O2" value="21.4" lower_limit="18.7" upper_limit="24.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 sero- [at Month 48] (N=29;32)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="386.1" lower_limit="203.9" upper_limit="731.1"/>
                    <measurement group_id="O2" value="NA">Not calculable as no subject had HPV-18 antibody titer equal to or above the assay cut-off value.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 sero- [at Month 84] (N=22;25)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="491.2" lower_limit="232.9" upper_limit="1036.0"/>
                    <measurement group_id="O2" value="NA">Not calculable as no subject had HPV-18 antibody titer equal to or above the assay cut-off value.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 sero+ [pre-vaccination] (N=3;3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.7" lower_limit="9.2" upper_limit="782.4"/>
                    <measurement group_id="O2" value="115.5" lower_limit="21.5" upper_limit="621.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 sero+ [at Month 7] (N=3;3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3014.5" lower_limit="446.3" upper_limit="20361.5"/>
                    <measurement group_id="O2" value="163.4" lower_limit="0.8" upper_limit="31959.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 sero+ [at Month 12] (N=3;3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3377.8" lower_limit="2563.9" upper_limit="4450.1"/>
                    <measurement group_id="O2" value="167.3" lower_limit="0.8" upper_limit="35164.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 sero+ [at Month 18] (N=3;3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3125.8" lower_limit="595.8" upper_limit="16398.4"/>
                    <measurement group_id="O2" value="254.9" lower_limit="0.4" upper_limit="172814.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 sero+ [at Month 24] (N=3;3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2493.0" lower_limit="261.2" upper_limit="23793.7"/>
                    <measurement group_id="O2" value="154.9" lower_limit="0.4" upper_limit="53341.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 sero+ [at Month 48] (N=1;2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="545.0">Data were not calculable because of too few subjects.</measurement>
                    <measurement group_id="O2" value="86.0" lower_limit="0.0" upper_limit="9662500000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 sero+ [at Month 84] (N=1;1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="532.0">Data were not calculable because of too few subjects.</measurement>
                    <measurement group_id="O2" value="968.0">Data were not calculable because of too few subjects.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms.</title>
        <description>Solicited local symptoms assessed were pain, redness and swelling. Any was defined as any solicited local symptom reported irrespective of intensity. Grade 3 pain was defined as pain that prevented normal activity. Grade 3 redness and swelling was defined as redness/swelling above 50 millimeter (mm).</description>
        <time_frame>Within 7 days (Days 0-6) after vaccination</time_frame>
        <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented and symptom sheets completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms.</title>
          <description>Solicited local symptoms assessed were pain, redness and swelling. Any was defined as any solicited local symptom reported irrespective of intensity. Grade 3 pain was defined as pain that prevented normal activity. Grade 3 redness and swelling was defined as redness/swelling above 50 millimeter (mm).</description>
          <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented and symptom sheets completed.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2830"/>
                <count group_id="O2" value="2831"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2411"/>
                    <measurement group_id="O2" value="1862"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="303"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1058"/>
                    <measurement group_id="O2" value="530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1080"/>
                    <measurement group_id="O2" value="428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms.</title>
        <description>Solicited general symptoms assessed were arthralgia, fatigue, gastrointestinal, headache, myalgia, rash, urticaria and fever (Fever = axillary temperature above 37.5 degrees Celsius (°C)). Any = any solicited general symptom reported irrespective of intensity and relationship to vaccination. Related = symptoms considered by the investigator to have a causal relationship to vaccination. Grade 3 symptoms = symptoms that prevented normal activity. Grade 3 urticaria = urticaria distributed on at least 4 body areas. Grade 3 fever = axillary temperature above 39.0°C.</description>
        <time_frame>Within 7 days (Days 0-6) after vaccination</time_frame>
        <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented and symptom sheets completed.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms.</title>
          <description>Solicited general symptoms assessed were arthralgia, fatigue, gastrointestinal, headache, myalgia, rash, urticaria and fever (Fever = axillary temperature above 37.5 degrees Celsius (°C)). Any = any solicited general symptom reported irrespective of intensity and relationship to vaccination. Related = symptoms considered by the investigator to have a causal relationship to vaccination. Grade 3 symptoms = symptoms that prevented normal activity. Grade 3 urticaria = urticaria distributed on at least 4 body areas. Grade 3 fever = axillary temperature above 39.0°C.</description>
          <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented and symptom sheets completed.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2832"/>
                <count group_id="O2" value="2832"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="580"/>
                    <measurement group_id="O2" value="439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade3 arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="323"/>
                    <measurement group_id="O2" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1116"/>
                    <measurement group_id="O2" value="916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="678"/>
                    <measurement group_id="O2" value="545"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="308"/>
                    <measurement group_id="O2" value="248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181"/>
                    <measurement group_id="O2" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="664"/>
                    <measurement group_id="O2" value="592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="335"/>
                    <measurement group_id="O2" value="312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1165"/>
                    <measurement group_id="O2" value="1074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="666"/>
                    <measurement group_id="O2" value="598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="878"/>
                    <measurement group_id="O2" value="622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="541"/>
                    <measurement group_id="O2" value="391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="185"/>
                    <measurement group_id="O2" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related rash</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any urticaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="258"/>
                    <measurement group_id="O2" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 urticaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related urticaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs).</title>
        <description>An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Grade 3 unsolicited AE = an event that prevented normal activity.
A related AE = event assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>Within 30 days (Days 0 – 29) post-vaccination period.</time_frame>
        <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs).</title>
          <description>An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Grade 3 unsolicited AE = an event that prevented normal activity.
A related AE = event assessed by the investigator as causally related to the study vaccination.</description>
          <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2877"/>
                <count group_id="O2" value="2870"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1153"/>
                    <measurement group_id="O2" value="1164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="208"/>
                    <measurement group_id="O2" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246"/>
                    <measurement group_id="O2" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs).</title>
        <description>SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects. A related SAE was defined as an event assessed by the investigator as causally related to the study vaccination.</description>
        <time_frame>Up to Month 48 and up to Month 84</time_frame>
        <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs).</title>
          <description>SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects. A related SAE was defined as an event assessed by the investigator as causally related to the study vaccination.</description>
          <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2877"/>
                <count group_id="O2" value="2870"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any SAEs, M48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="286"/>
                    <measurement group_id="O2" value="266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAEs, M48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAEs, M84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="291"/>
                    <measurement group_id="O2" value="269"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAEs, M84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Related or Fatal Serious Adverse Event.</title>
        <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
        <time_frame>Up to Month 84</time_frame>
        <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Related or Fatal Serious Adverse Event.</title>
          <description>Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
          <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2877"/>
                <count group_id="O2" value="2870"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fatal AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Any AE/SAE Leading to Premature Discontinuation of the Study.</title>
        <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
        <time_frame>Up to Month 84</time_frame>
        <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Any AE/SAE Leading to Premature Discontinuation of the Study.</title>
          <description>An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.</description>
          <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2877"/>
                <count group_id="O2" value="2870"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting New Onset of Chronic Disease (NOCDs).</title>
        <description>NOCDs include autoimmune disorders, asthma and type I diabetes.</description>
        <time_frame>Up to Month 48</time_frame>
        <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting New Onset of Chronic Disease (NOCDs).</title>
          <description>NOCDs include autoimmune disorders, asthma and type I diabetes.</description>
          <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2877"/>
                <count group_id="O2" value="2870"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting New Onset of Autoimmune Disease (NOADs).</title>
        <time_frame>Up to Month 48</time_frame>
        <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting New Onset of Autoimmune Disease (NOADs).</title>
          <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2877"/>
                <count group_id="O2" value="2870"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Reporting Medically Significant Conditions (MAEs).</title>
        <description>Medically significant conditions were defined as: AEs prompting emergency room or physician visits that were not (1) related to common diseases or (2) routine visits for physical examination or vaccination, or SAEs that were not related to common diseases. Common diseases included: upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervicovaginal yeast infections, menstrual cycle abnormalities and injury.</description>
        <time_frame>Up to Month 48</time_frame>
        <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Reporting Medically Significant Conditions (MAEs).</title>
          <description>Medically significant conditions were defined as: AEs prompting emergency room or physician visits that were not (1) related to common diseases or (2) routine visits for physical examination or vaccination, or SAEs that were not related to common diseases. Common diseases included: upper respiratory infections, sinusitis, pharyngitis, gastroenteritis, urinary tract infections, cervicovaginal yeast infections, menstrual cycle abnormalities and injury.</description>
          <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2877"/>
                <count group_id="O2" value="2870"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1170"/>
                    <measurement group_id="O2" value="1140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Pregnancies and Their Outcomes.</title>
        <description>Pregnancy outcomes are live infant, premature live infant, elective termination, ectopic pregnancy, spontaneous abortion, lost to follow-up and pregnancy ongoing. For each category it was specified if the infant presents congenital anomaly (CA) or no apparent congenital anomaly (No ACA).</description>
        <time_frame>Up to Month 48</time_frame>
        <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Pregnancies and Their Outcomes.</title>
          <description>Pregnancy outcomes are live infant, premature live infant, elective termination, ectopic pregnancy, spontaneous abortion, lost to follow-up and pregnancy ongoing. For each category it was specified if the infant presents congenital anomaly (CA) or no apparent congenital anomaly (No ACA).</description>
          <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="359"/>
                <count group_id="O2" value="357"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Live infant No ACA, M48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259"/>
                    <measurement group_id="O2" value="249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Live infant CA, M48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elective termination No ACA, M48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Elective termination CA, M48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ectopic pregnancy, M48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spontaneous abortion No ACA, M48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spontaneous abortion CA, M48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stillbirth No ACA, M48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lost to follow-up, M48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Using the Type Assignment Algorithm (TAA)</title>
        <description>CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.
Detection was done on subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.
TAA: Type assignment algorithm. The lesion was assigned to an HPV type found in the lesion if
the same HPV type was found in at least one of the two (closest) preceding cytology samples, or
none of the HPV types found in the lesion were found in any of the two preceding cytology samples (isolate HPV types)</description>
        <time_frame>Up to Month 48</time_frame>
        <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Using the Type Assignment Algorithm (TAA)</title>
          <description>CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer.
Detection was done on subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.
TAA: Type assignment algorithm. The lesion was assigned to an HPV type found in the lesion if
the same HPV type was found in at least one of the two (closest) preceding cytology samples, or
none of the HPV types found in the lesion were found in any of the two preceding cytology samples (isolate HPV types)</description>
          <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2224"/>
                <count group_id="O2" value="2190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16/18 DNA- (N=2224;2190)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 DNA- (N=2167;2131)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 DNA- (N=2203;2165)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18</title>
        <description>Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type(s) by PCR in cervical samples at 2 consecutive evaluations over approximately a 6-month interval. Detection was done in: - DNA- and sero-/+: subjects HPV DNA negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by ELISA at baseline (Month 0). - Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
        <time_frame>Up to Month 84</time_frame>
        <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18</title>
          <description>Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type(s) by PCR in cervical samples at 2 consecutive evaluations over approximately a 6-month interval. Detection was done in: - DNA- and sero-/+: subjects HPV DNA negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by ELISA at baseline (Month 0). - Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
          <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2124"/>
                <count group_id="O2" value="2109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16/18, DNA- and sero- subjects (N=1815;1786)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, DNA- and sero- subjects (N=1482;1466)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, DNA- and sero- subjects (N=1535;1511)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16/18, DNA- and sero+ subjects (N=851;837)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, DNA- and sero+ subjects (N=574;573)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, DNA- and sero+ subjects (N=541;534)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16/18, overall (N=2124;2109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, overall (N=2073;2055)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, overall (N=2108;2085)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Persistent Infection (12-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18</title>
        <description>Persistent cervical HPV infection (12-month definition) was defined as the detection of the same HPV type(s) PCR in cervical samples at all available time points over approximately a 12-month interval (evaluations are planned at approximately 6-month intervals). - DNA- and sero-/+: subjects HPV DNA negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by ELISA at baseline (Month 0). - Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
        <time_frame>Up to Month 84</time_frame>
        <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Persistent Infection (12-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18</title>
          <description>Persistent cervical HPV infection (12-month definition) was defined as the detection of the same HPV type(s) PCR in cervical samples at all available time points over approximately a 12-month interval (evaluations are planned at approximately 6-month intervals). - DNA- and sero-/+: subjects HPV DNA negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by ELISA at baseline (Month 0). - Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
          <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2093"/>
                <count group_id="O2" value="2081"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16/18, DNA- and sero- subjects (N=1789;1764)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, DNA- and sero- subjects (N=1464;1447)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, DNA- and sero- subjects (N=1513;1494)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16/18, DNA- and sero+ subjects (N=835;825)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, DNA- and sero+ subjects (N=562;567)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, DNA- and sero+ subjects (N=532;523)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16/18, overall (N=2093;2081)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, overall (N=2043;2030)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, overall (N=2077;2057)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Persistent Infection (6-month Definition) With Oncogenic HPV Types Individually or in Combinations.</title>
        <description>Persistent cervical HPV infection (6-month definition) = detection of the same HPV type(s) by PCR in cervical samples at 2 consecutive evaluations over approximately a 6-month interval. Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. Detection was done in subjects HPV DNA- for the corresponding HPV type at baseline (at month 0 and Month 6) regardless of initial serostatus. HPV-HRW=All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18. HPV-HR=High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.</description>
        <time_frame>Up to Month 84</time_frame>
        <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Persistent Infection (6-month Definition) With Oncogenic HPV Types Individually or in Combinations.</title>
          <description>Persistent cervical HPV infection (6-month definition) = detection of the same HPV type(s) by PCR in cervical samples at 2 consecutive evaluations over approximately a 6-month interval. Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. Detection was done in subjects HPV DNA- for the corresponding HPV type at baseline (at month 0 and Month 6) regardless of initial serostatus. HPV-HRW=All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18. HPV-HR=High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68.</description>
          <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2125"/>
                <count group_id="O2" value="2111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16 (N=2073;2055)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 (N=2108;2085)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31 (N=2073;2090)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-33 (N=2105;2094)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-35 (N=2112;2101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-39 (N=2097;2078)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-45 (N=2106;2088)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-51 (N=2071;2072)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-52 (N=2060;2058)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-56 (N=2100;2081)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-58 (N=2098;2092)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-59 (N=2105;2083)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-66 (N=2089;2080)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-68 (N=2084;2085)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31/45 (N=2121;2109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31/45/33/52/58 (N=2125;2111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-39/45/59/68 (N=2125;2111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31/33/35/52/58 (N=2125;2111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31/45/33/52/58/35/39/51/56/59 (N=2125;2111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206"/>
                    <measurement group_id="O2" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-HRW (N=2125;2111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255"/>
                    <measurement group_id="O2" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-HR (N=2125;2111)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="262"/>
                    <measurement group_id="O2" value="330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Persistent Infection (12-month Definition) With Oncogenic HPV Types Individually or in Combinations.</title>
        <description>Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. subjects HPV DNA- for the corresponding HPV type at Month 0 6, regardless of initial serostatus. HPV-HRW=All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18 HPV-HR=High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 , 68</description>
        <time_frame>Up to Month 84</time_frame>
        <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Persistent Infection (12-month Definition) With Oncogenic HPV Types Individually or in Combinations.</title>
          <description>Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. subjects HPV DNA- for the corresponding HPV type at Month 0 6, regardless of initial serostatus. HPV-HRW=All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18 HPV-HR=High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 , 68</description>
          <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2094"/>
                <count group_id="O2" value="2083"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16 (N=2043;2030)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 (N=2077;2057)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31 (N=2044;2062)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-33 (N=2074;2068)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-35 (N=2081;2073)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-39 (N=2067;2050)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-45 (N=2076;2060)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-51 (N=2040;2045)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-52 (N=2029;2031)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-56 (N=2071;2054)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-58 (N=2067;2065)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-59 (N=2074;2055)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-66 (N=2058;2052)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-68 (N=2053;2057)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31/45 (N=2091;2081)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31/45/33/52/58 (N=2094;2083)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-39/45/59/68 (N=2094;2083)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31/33/35/52/58 (N=2094;2083)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31/45/33/52/58/35/39/51/56/59 (N=2094;2083)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                    <measurement group_id="O2" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-HRW (N=2094;2083)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-HR (N=2094;2083)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With HPV-16 and/or -18 Cervical Infection Detected Within the Lesional Component of the Cervical Tissue Specimen</title>
        <description>CIN2+ was defined as CIN grades 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer. Detection was done in: - DNA- and sero-: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative (sero-) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0). - Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline. Note: Results for seropositive status were not analysed.</description>
        <time_frame>Up to Month 84</time_frame>
        <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With HPV-16 and/or -18 Cervical Infection Detected Within the Lesional Component of the Cervical Tissue Specimen</title>
          <description>CIN2+ was defined as CIN grades 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer. Detection was done in: - DNA- and sero-: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative (sero-) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0). - Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline. Note: Results for seropositive status were not analysed.</description>
          <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2168"/>
                <count group_id="O2" value="2146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16/18, DNA- and sero- subjects (N=1852;1818)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, DNA- and sero- subjects (N=1507;1491)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, DNA- and sero- subjects (N=1565;1541)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16/18, overall (N=2168;2146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, overall (N=2112;2090)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, overall (N=2149;2122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Within the Lesional Component of the Cervical Tissue Specimen</title>
        <description>CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer. Detection was done in: - DNA- and sero-/+: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0). - Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
        <time_frame>Up to Month 84</time_frame>
        <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Within the Lesional Component of the Cervical Tissue Specimen</title>
          <description>CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer. Detection was done in: - DNA- and sero-/+: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative/positive (sero-/+) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0). - Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline.</description>
          <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2168"/>
                <count group_id="O2" value="2146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16/18, DNA- and sero- subjects (N=1852;1818)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, DNA- and sero- subjects (N=1507;1491)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, DNA- and sero- subjects (N=1565;1541)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16/18, DNA- and sero+ subjects (N=870;848)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, DNA- and sero+ subjects (N=588;583)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, DNA- and sero+ subjects (N=552;539)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16/18, overall (N=2168;2146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, overall (N=2112;2090)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, overall (N=2149;2122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Within the Lesional Component of the Cervical Tissue Specimen</title>
        <time_frame>Up to Month 84</time_frame>
        <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Within the Lesional Component of the Cervical Tissue Specimen</title>
          <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2733"/>
                <count group_id="O2" value="2735"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16/18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Irrespective of HPV Cervical Infection and Irrespective of Baseline HPV DNA Status</title>
        <description>CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer. Detection was done on all subjects irrespective of their baseline HPV DNA status.</description>
        <time_frame>Up to Month 84</time_frame>
        <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Irrespective of HPV Cervical Infection and Irrespective of Baseline HPV DNA Status</title>
          <description>CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer. Detection was done on all subjects irrespective of their baseline HPV DNA status.</description>
          <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2733"/>
                <count group_id="O2" value="2735"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179"/>
                    <measurement group_id="O2" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Any Cytological Abnormalities Associated With HPV-16 or HPV-18 Cervical Infection</title>
        <description>Cytological abnormalities = atypical squamous cells of undetermined significance (ASC-US). Detection was done in: - DNA- and sero-: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative (sero-) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0). - Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline. Results for seropositive status were not analysed.</description>
        <time_frame>Up to Month 84</time_frame>
        <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Any Cytological Abnormalities Associated With HPV-16 or HPV-18 Cervical Infection</title>
          <description>Cytological abnormalities = atypical squamous cells of undetermined significance (ASC-US). Detection was done in: - DNA- and sero-: subjects HPV deoxyribonucleic acid (DNA) negative (DNA-) at Month 0 and Month 6 for the corresponding HPV-type and seronegative (sero-) for HPV-16 and/or HPV-18 by Enzyme-linked Immunosorbent Assay (ELISA) at baseline (Month 0). - Overall: subjects DNA- at Month 0 and Month 6 for the corresponding HPV-type and regardless of initial serostatus at baseline. Results for seropositive status were not analysed.</description>
          <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2168"/>
                <count group_id="O2" value="2146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16/18, DNA- and sero- subjects (N=1852;1818)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16, DNA- and sero- subjects (N=1507;1491)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18, DNA- and sero- subjects (N=1565;1541)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16/18, overall (N=2168;2146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16 (N=2112;2090)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 (N=2149;2122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Cytological Abnormalities Associated With Oncogenic HPV Types Individually or in Combinations</title>
        <description>Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. Detection was done in subjects who were HPV DNA negative for the corresponding HPV type at baseline (at month 0 and Month 6) regardless of initial serostatus. HRW-HPV= All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18 HPV-HR= High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68</description>
        <time_frame>Up to Month 48</time_frame>
        <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Cytological Abnormalities Associated With Oncogenic HPV Types Individually or in Combinations</title>
          <description>Oncogenic HPV types included HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68. Detection was done in subjects who were HPV DNA negative for the corresponding HPV type at baseline (at month 0 and Month 6) regardless of initial serostatus. HRW-HPV= All high-risk (oncogenic) HPV types excluding HPV-16 and HPV-18 HPV-HR= High-risk (oncogenic) HPV types: HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68</description>
          <population>The According-To-Protocol cohort for efficacy included subjects who had a normal or low-grade cytology (negative or atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesion (LSIL)) at Month 0, who received 3 doses. A 15% subset of women enrolled with prior history of HPV infection was excluded.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2169"/>
                <count group_id="O2" value="2146"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16 (N=2112;2090)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18 (N=2149;2122)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31 (N=2117;2127)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-33 (N=2149;2130)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-35 (N=2156;2137)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-39 (N=2141;2114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-45 (N=2150;2125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-51 (N=2115;2107)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-52 (N=2103;2095)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-56 (N=2144;2115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-58 (N=2142;2128)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-59 (N=2147;2120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-66 (N=2133;2117)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-68 (N=2128;2120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31/45 (N=2165;2146)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31/45/33/52/58 (N=2169;2148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-39/45/59/68 (N=2169;2148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31/33/35/52/58 (N=2169;2148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-31/45/33/52/58/35/39/51/56/59 (N=2169;2148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119"/>
                    <measurement group_id="O2" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-HRW (N=2169;2148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-HR (N=2169;2148)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                    <measurement group_id="O2" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Histopathologically Confirmed Reduction of Local Cervical Therapy</title>
        <description>Detection was done on all subjects irrespective of their baseline HPV DNA status.</description>
        <time_frame>Up to Month 84</time_frame>
        <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Histopathologically Confirmed Reduction of Local Cervical Therapy</title>
          <description>Detection was done on all subjects irrespective of their baseline HPV DNA status.</description>
          <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2733"/>
                <count group_id="O2" value="2735"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With First Colposcopy</title>
        <description>Detection was done on all subjects irrespective of their baseline HPV DNA status.</description>
        <time_frame>Up to Month 84</time_frame>
        <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With First Colposcopy</title>
          <description>Detection was done on all subjects irrespective of their baseline HPV DNA status.</description>
          <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2734"/>
                <count group_id="O2" value="2736"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="506"/>
                    <measurement group_id="O2" value="560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18 and/or With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection</title>
        <description>Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type(s) by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval. CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer. Detection was done on all subjects irrespective of their baseline HPV DNA and serostatus.</description>
        <time_frame>Up to Month 84</time_frame>
        <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18 and/or With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)1+ Associated With HPV-16 and/or -18 Cervical Infection</title>
          <description>Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type(s) by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval. CIN1+ was defined as CIN grades 1, 2 and 3, adenocarcinoma in situ (AIS) and invasive cervical cancer. Detection was done on all subjects irrespective of their baseline HPV DNA and serostatus.</description>
          <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2768"/>
                <count group_id="O2" value="2778"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16/18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 or HPV-18 and/or With Histopathologically-confirmed CIN1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Using the HPV Type Assignment Algorithm (TAA).</title>
        <description>Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type(s) by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval. Detection was done on all subjects irrespective of their baseline HPV DNA and serostatus. The lesion was assigned to an HPV type found in the lesion if (1) the same HPV type was found in at least 1 of the 2 (closest) preceding cytology samples, or (2) none of the HPV types found in the lesion were found in any of the 2 preceding cytology samples (isolate HPV types)</description>
        <time_frame>Up to Month 84</time_frame>
        <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
        <group_list>
          <group group_id="O1">
            <title>Cervarix Group</title>
            <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
          <group group_id="O2">
            <title>Aluminium Hydroxide Group</title>
            <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Persistent Infection (6-month Definition) With HPV-16 or HPV-18 and/or With Histopathologically-confirmed CIN1+ Associated With HPV-16 and/or -18 Cervical Infection Detected Using the HPV Type Assignment Algorithm (TAA).</title>
          <description>Persistent cervical HPV infection (6-month definition) was defined as the detection of the same HPV type(s) by polymerase chain reaction (PCR) in cervical samples at 2 consecutive evaluations over approximately a 6-month interval. Detection was done on all subjects irrespective of their baseline HPV DNA and serostatus. The lesion was assigned to an HPV type found in the lesion if (1) the same HPV type was found in at least 1 of the 2 (closest) preceding cytology samples, or (2) none of the HPV types found in the lesion were found in any of the 2 preceding cytology samples (isolate HPV types)</description>
          <population>The Total Vaccinated cohort included all subjects with at least one vaccine administration documented.</population>
          <units>Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2768"/>
                <count group_id="O2" value="2778"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HPV-16/18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92"/>
                    <measurement group_id="O2" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HPV-18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>SAEs: from the beginning of the study up to Month 84. Unsolicited AEs: within 30 days (Days 0-29) post-vaccination period). Solicited AEs: During the 7-day (Days 0-6) post-vaccination period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cervarix Group</title>
          <description>Subjects received 3 doses of Cervarix™ vaccine. Cervarix vaccine was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
        </group>
        <group group_id="E2">
          <title>Aluminium Hydroxide Group</title>
          <description>Subjects received 3 doses of Aluminium Hydroxide [Al(OH)3]. Aluminium Hydroxide was administered intramuscularly into the deltoid region of the non-dominant arm according to a 0, 1, 6 months schedule.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="291" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="269" subjects_at_risk="2871"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Placental transfusion syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Splenic infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchogenic cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Pyloric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Addison’s disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Basedow’s disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Thyroid cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Angle closure glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Macular oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Retinal vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Epiploic appendagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Haemorrhoids thrombosed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Ileus paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Impaired gastric emptying</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Oedematous pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Tooth impacted</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Ill-defined disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Incarcerated hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Salpingitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Amniotic cavity infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Burn infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Chlamydial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Chronic tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Cystitis klebsiella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Genitourinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Lyme disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Opisthorchiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Pasteurella infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Pelvic inflammatory disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Pyonephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Renal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Typhoid fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Postoperative abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Anaesthetic complication pulmonary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Bone fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Post lumbar puncture syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Ulnar nerve injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Urinary retention postoperative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2871"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Cholesterosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Arthritis reactive</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Joint instability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Joint range of motion decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Lupus-like syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Periostitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of the cervix</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Adenoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Anaplastic astrocytoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Breast cancer female</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Breast cancer stage II</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Cervix cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Chronic myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Fibroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Glioblastoma multiforme</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Hodgkin’s disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Liposarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Mediastinum neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Nasopharyngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Ovarian germ cell teratoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Ovarian neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Pituitary tumour benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Renal oncocytoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Teratoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Vaginal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Basal ganglia haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Cerebral cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Diabetic coma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Intracranial haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Vertebral artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous complete</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous incomplete</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Blighted ovum</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Abortion threatened</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Pre-eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Premature labour</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Ruptured ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Arrested labour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Gestational hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Premature delivery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Abortion complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Foetal death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Haemorrhage in pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Hyperemesis gravidarum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Placenta accreta</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Postpartum haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Premature rupture of membranes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Retained products of conception</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Stillbirth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Threatened labour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Prolonged labour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Anorexia nervosa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Conversion disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Depression suicidal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Calculus bladder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Ureteric obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Dysfunctional uterine bleeding</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Bartholin’s cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Ovarian cyst torsion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Adnexal torsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Bartholinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Colpocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Endometrial hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Endosalpingiosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Genital prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Pelvic prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Polycystic ovaries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Polymyalgia rheumatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Uterine atony</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Uterine cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Uterovaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Asthmatic crisis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Nasal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Nasal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Sinus disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Homicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2871"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2411" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1862" subjects_at_risk="2871"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2411" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1862" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" subjects_affected="1058" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="530" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="1080" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="428" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="580" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="439" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1116" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="916" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="308" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="248" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="664" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="592" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1165" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="1074" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="878" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="622" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="185" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="124" subjects_at_risk="2871"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="258" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="201" subjects_at_risk="2871"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="203" subjects_at_risk="2881"/>
                <counts group_id="E2" subjects_affected="222" subjects_at_risk="2871"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

